Successful treatment of hepatitis B-associated leukocytoclastic vasculitis with lamivudine treatment in a child patient.
Chronic hepatitis B infection (HBI) has many extrahepatic manifestations such as vasculitis, glomerulonephritis, arthritis, dermatitis, pulmonary disease, and skin manifestations. The mechanism of these manifestations is thought to be immune mediated. Immune-suppressive treatment may enhance viral replication and worsen hepatic disease. Lamivudine is a nucleoside analogue used in chronic HBI treatment that works by suppressing replication of the hepatitis B virus (HBV). Recently, several reports have suggested that lamivudine treats vasculitis associated with HBV infection in adults. However, there are no data in the literature for children. Herein, we report a child with leukocytoclastic vasculitis due to chronic HBI who was successfully treated with lamivudine.
Surmali Onay
Ozge
O
Department of Pediatric Nephrology, Başkent University Faculty of Medicine, 6. Cadde, No:72/3, 06490 Bahçelievler, Ankara, Turkey.
Baskin
Esra
E
Ozçay
Figen
F
Melek
Engin
E
Canan
Oguz
O
Bilezikçi
Banu
B
D000998:Antiviral Agents / Q000008:administration & dosage; D001808:Blood Vessels / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D002648:Child; D004334:Drug Administration Schedule; D005260:Female; D006509:Hepatitis B / Q000150:complications* / Q000276:immunology* / Q000503:physiopathology; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D008099:Liver / Q000473:pathology / Q000503:physiopathology / Q000821:virology; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage*; D016896:Treatment Outcome; D014421:Turkey; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology
D000998:Antiviral Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine